Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research report released on Friday.

A number of other research firms also recently weighed in on TVRD. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Piper Sandler lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday, October 13th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Down 2.9%

TVRD stock opened at $4.69 on Friday. Tvardi Therapeutics has a twelve month low of $3.74 and a twelve month high of $43.65. The company has a market cap of $43.99 million, a PE ratio of -0.49 and a beta of 0.09. The business’s 50-day simple moving average is $4.21 and its 200 day simple moving average is $16.81.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in shares of Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics during the 2nd quarter worth about $43,000. Headlands Technologies LLC bought a new stake in Tvardi Therapeutics during the 2nd quarter worth about $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $92,000. Finally, Squarepoint Ops LLC bought a new position in shares of Tvardi Therapeutics in the third quarter worth about $318,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.